Page last updated: 2024-12-05

dipicolinic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dipicolinic acid, also known as pyridine-2,6-dicarboxylic acid, is a heterocyclic dicarboxylic acid. It is a white solid that is soluble in water and ethanol. Dipicolinic acid is a key component of bacterial endospores, which are highly resistant to heat, radiation, and chemicals. It is believed to contribute to the resistance of endospores by stabilizing the DNA and proteins within the spore. Dipicolinic acid is synthesized by bacteria from dipicolinate synthase, which catalyzes the condensation of pyruvate and aspartate. Dipicolinic acid is studied for its potential use in the development of new antibiotics and other therapeutic agents. It has also been investigated for its ability to bind to metals and its potential use in environmental remediation.'

dipicolinic acid : A pyridinedicarboxylic acid carrying two carboxy groups at positions 2 and 6. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID10367
CHEMBL ID284104
CHEBI ID46837
SCHEMBL ID34595
MeSH IDM0046076

Synonyms (71)

Synonym
EU-0033484
ue81s5cq0g ,
unii-ue81s5cq0g
chembl284104 ,
bdbm26116
pyridine carboxylate, 6d
IFLAB1_001781
smr000034075
MLS000080748
pydch2
pyridine-2,6-dicarboxylic acid
l-042,134
OPREA1_533632
STK092939
inchi=1/c7h5no4/c9-6(10)4-2-1-3-5(8-4)7(11)12/h1-3h,(h,9,10)(h,11,12
dipicolinate
499-83-2
dipicolinic acid
nsc176
nsc-176
2,6-dipicolinic acid
2,6-dicarboxypyridine
2,6-pyridinedicarboxylic acid
2,6-pyridinedicarboxylic acid, 99%
SR-01000600024-2
DB04267
CHEBI:46837 ,
einecs 207-894-3
nsc 176
2,6-pyridinedicarboxylate
B63A70CE-B9AB-4EA2-834A-6C7634226BB0
AC-704
AKOS000112829
HMS1417A21
P0554
A7431
NCGC00071864-02
tox21_301129
dtxcid602043
NCGC00255028-01
dtxsid7022043 ,
cas-499-83-2
BBL012080
HMS2231H20
CCG-44216
F0451-0137
FT-0610741
2,6-dipiclinic acid
2,6-dicarboxypyridine [inci]
6-carboxypicolinic acid
CL0252
AM82010
SCHEMBL34595
2,6-pyridine dicarboxylic acid
W-105996
2,6-pyridinedicarboxylic acid-2,6-dipicolinic acid
pyridinedicarboxylic acid-(2,6)
PS-8736
mfcd00006299
4IH3
Z57202012
2,6-pyridinedicarboxylic acid, for ion chromatography, >=99.5% (t)
2,6-di-carboxy-pyridine
CS-0016012
SY001460
Q417164
pyridine-2
pyridine-2,6-dicarboxylicacid
EN300-18133
HY-Y1024
dipicolinic acid, beauveria sp.

Research Excerpts

Overview

Dipicolinic acid (DPA) is a chelate capable of binding to a variety of lanthanide ions to make them luminescent in the visible range. It is an essential component for the protection of DNA in bacterial endospores and is often used as a biomarker for spore detection.

ExcerptReferenceRelevance
"Dipicolinic acid (DPA) is an anthrax biomarker. "( Three novel metal-organic frameworks with different coordination modes for trace detection of anthrax biomarkers.
Cong, Z; Fedin, VP; Gao, E; Kosinova, M; Wu, S; Yao, W; Zhang, Y; Zhu, M, 2021
)
2.06
"Dipicolinic acid (DPA) is an essential component for the protection of DNA in bacterial endospores and is often used as a biomarker for spore detection. "( pH-induced changes in Raman, UV-vis absorbance, and fluorescence spectra of dipicolinic acid (DPA).
Andersson, M; Andersson, PO; Dahlberg, T; Landström, L; Malyshev, D; Öberg, R, 2022
)
2.39
"Dipicolinic acid (DPA) is a specific molecule of bacterial spores which is essential to their resistance to various stresses such as ultraviolet (UV) exposure and to their germination. "( Uptake of UVc induced photoproducts of dipicolinic acid by Bacillus subtilis spores - Effects on the germination and UVc resistance of the spores.
Dikec, J; Lavaud, M; Pacheco, M; Perrier-Cornet, JM; Winckler, P, 2022
)
2.43
"Dipicolinic acid (DPA) is a chelate capable of binding to a variety of lanthanide ions to make them luminescent in the visible range. "( Magnetic separation-enhanced photoluminescence detection of dipicolinic acid and quenching detection of Cu(II) ions.
Jeon, H; Kim, D; Kim, T; Lee, JR, 2024
)
3.13
"Dipicolinic acid (DPA) is a biologically derived aromatic di-acid that has a similar structure to isophthalic acid."( Engineering the production of dipicolinic acid in E. coli.
Fahnhorst, GW; Hoye, TR; McClintock, MK; Zhang, K, 2018
)
1.49
"Dipicolinic acid (DPA) is a multi-functional agent for cosmetics, antimicrobial products, detergents, and functional polymers. "( Increased dipicolinic acid production with an enhanced spoVF operon in Bacillus subtilis and medium optimization.
Hagihara, H; Ozaki, K; Sumitomo, N; Takahashi, F, 2015
)
2.26
"Dipicolinic acid (DPA) is an important chemical marker for the detection of bacterial spores. "( Rapid onsite detection of bacterial spores of biothreat importance by paper-based colorimetric method using erbium-pyrocatechol violet complex.
Lakshmana Rao, PV; Shivakiran, MS; Venkataramana, M, 2016
)
1.88
"Dipicolinic acid (DPA) is a major component of bacterial endospores, comprising 5-15% of the spore dry weight, and is important for spore stability and resistance properties. "( EtfA catalyses the formation of dipicolinic acid in Clostridium perfringens.
Melville, SB; Orsburn, BC; Popham, DL, 2010
)
2.09
"Dipicolinic acid (DPA) is an excellent marker compound for bacterial spores, including those of Bacillus anthracis (anthrax). "( Quantitative surface-enhanced Raman spectroscopy of dipicolinic acid--towards rapid anthrax endospore detection.
Bell, SE; Mackle, JN; Sirimuthu, NM, 2005
)
2.02

Effects

ExcerptReferenceRelevance
"Dipicolinic acid (DPA) has been recognized as a biomarker for spore-forming bacteria."( Gold nanocluster-based fluorescence sensing probes for detection of dipicolinic acid.
Baig, MMF; Chen, YC, 2019
)
1.47

Actions

ExcerptReferenceRelevance
"Dipicolinic acid (DPA) can cause neurotoxicity and is abundant in bacterial spores. "( Gold nanoparticle-based colorimetric sensing of dipicolinic acid from complex samples.
Baig, MMF; Chen, YC, 2018
)
2.18

Dosage Studied

ExcerptRelevanceReference
" The reproducibility, repeatability, and applicability of the analysis to pharmaceutical dosage forms and human serum samples were also examined."( Electrochemical DNA biosensor based on poly(2,6-pyridinedicarboxylic acid) modified glassy carbon electrode for the determination of anticancer drug gemcitabine.
Pekyardımcı, Ş; Tığ, GA; Zeybek, B, 2016
)
0.43
" Detection limit of Tb/Eu@bio-MOF-1 for DPA was 34nM, which was much lower than an infectious dosage of Bacillus anthracis spores (60μM) for human being."( Rapid and facile ratiometric detection of an anthrax biomarker by regulating energy transfer process in bio-metal-organic framework.
Li, B; Ma, H; Zhang, L; Zhang, Y; Zheng, Y, 2016
)
0.43
"3 nM, which is four orders of magnitude lower than an infectious dosage of anthrax spores for human beings (60 μM)."( Dual-emission of silicon nanoparticles encapsulated lanthanide-based metal-organic frameworks for ratiometric fluorescence detection of bacterial spores.
Cui, Z; Guo, R; Li, H; Li, M; Mei, S; Qiu, Y; Wang, L; Wei, C; Wei, X; Wen, Z; Xie, F; Yang, B; Yang, D; Zhang, W, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
pyridinedicarboxylic acidAny member of the class of pyridines carrying two carboxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency7.94330.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency1.41250.004023.8416100.0000AID485290
Chain A, Beta-lactamaseEscherichia coli K-12Potency2.81840.044717.8581100.0000AID485294
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency28.18380.140911.194039.8107AID2451
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency8.91250.177814.390939.8107AID2147
15-lipoxygenase, partialHomo sapiens (human)Potency1.00000.012610.691788.5700AID887
phosphopantetheinyl transferaseBacillus subtilisPotency3.98110.141337.9142100.0000AID1490
thyroid stimulating hormone receptorHomo sapiens (human)Potency1.58490.001318.074339.8107AID926
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.43640.000229.305416,493.5996AID743075
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.79430.035520.977089.1251AID504332
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Lysine-specific demethylase 4EHomo sapiens (human)IC50 (µMol)120.00000.20001.95696.3096AID1798635
Metallo-beta-lactamase type 2Serratia marcescensIC50 (µMol)3.03003.03003.03003.0300AID1451106
Metallo-beta-lactamase L1 type 3Stenotrophomonas maltophiliaIC50 (µMol)7.80007.80007.80007.8000AID107428
2-amino-3-carboxymuconate-6-semialdehyde decarboxylaseHomo sapiens (human)Ki15.20002.56002.56002.5600AID1744124
Beta-lactamase class B VIM-2 Pseudomonas aeruginosaIC50 (µMol)1.66001.66004.38678.0000AID1451107
Beta-lactamase VIM-1 Pseudomonas aeruginosaIC50 (µMol)41.60009.30009.30009.3000AID530343
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
regulation of gene expressionLysine-specific demethylase 4EHomo sapiens (human)
chromatin remodelingLysine-specific demethylase 4EHomo sapiens (human)
glyoxylate catabolic process4-hydroxy-2-oxoglutarate aldolase, mitochondrialHomo sapiens (human)
4-hydroxyproline catabolic process4-hydroxy-2-oxoglutarate aldolase, mitochondrialHomo sapiens (human)
oxalate metabolic process4-hydroxy-2-oxoglutarate aldolase, mitochondrialHomo sapiens (human)
pyruvate biosynthetic process4-hydroxy-2-oxoglutarate aldolase, mitochondrialHomo sapiens (human)
glyoxylate metabolic process4-hydroxy-2-oxoglutarate aldolase, mitochondrialHomo sapiens (human)
N-acetylneuraminate catabolic process4-hydroxy-2-oxoglutarate aldolase, mitochondrialHomo sapiens (human)
tryptophan catabolic process2-amino-3-carboxymuconate-6-semialdehyde decarboxylaseHomo sapiens (human)
negative regulation of quinolinate biosynthetic process2-amino-3-carboxymuconate-6-semialdehyde decarboxylaseHomo sapiens (human)
picolinic acid biosynthetic process2-amino-3-carboxymuconate-6-semialdehyde decarboxylaseHomo sapiens (human)
regulation of 'de novo' NAD biosynthetic process from tryptophan2-amino-3-carboxymuconate-6-semialdehyde decarboxylaseHomo sapiens (human)
secondary metabolic process2-amino-3-carboxymuconate-6-semialdehyde decarboxylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (11)

Processvia Protein(s)Taxonomy
metal ion bindingLysine-specific demethylase 4EHomo sapiens (human)
histone H3K9me2/H3K9me3 demethylase activityLysine-specific demethylase 4EHomo sapiens (human)
histone H3K9 demethylase activityLysine-specific demethylase 4EHomo sapiens (human)
protein binding4-hydroxy-2-oxoglutarate aldolase, mitochondrialHomo sapiens (human)
4-hydroxy-2-oxoglutarate aldolase activity4-hydroxy-2-oxoglutarate aldolase, mitochondrialHomo sapiens (human)
protein homodimerization activity4-hydroxy-2-oxoglutarate aldolase, mitochondrialHomo sapiens (human)
(4S)-4-hydroxy-2-oxoglutarate aldolase activity4-hydroxy-2-oxoglutarate aldolase, mitochondrialHomo sapiens (human)
N-acetylneuraminate lyase activity4-hydroxy-2-oxoglutarate aldolase, mitochondrialHomo sapiens (human)
aminocarboxymuconate-semialdehyde decarboxylase activity2-amino-3-carboxymuconate-6-semialdehyde decarboxylaseHomo sapiens (human)
protein binding2-amino-3-carboxymuconate-6-semialdehyde decarboxylaseHomo sapiens (human)
zinc ion binding2-amino-3-carboxymuconate-6-semialdehyde decarboxylaseHomo sapiens (human)
hydrolase activity2-amino-3-carboxymuconate-6-semialdehyde decarboxylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
nucleusLysine-specific demethylase 4EHomo sapiens (human)
nucleoplasmLysine-specific demethylase 4EHomo sapiens (human)
chromatinLysine-specific demethylase 4EHomo sapiens (human)
nucleusLysine-specific demethylase 4EHomo sapiens (human)
mitochondrion4-hydroxy-2-oxoglutarate aldolase, mitochondrialHomo sapiens (human)
mitochondrial matrix4-hydroxy-2-oxoglutarate aldolase, mitochondrialHomo sapiens (human)
mitochondrion4-hydroxy-2-oxoglutarate aldolase, mitochondrialHomo sapiens (human)
cytosol2-amino-3-carboxymuconate-6-semialdehyde decarboxylaseHomo sapiens (human)
cytosol2-amino-3-carboxymuconate-6-semialdehyde decarboxylaseHomo sapiens (human)
cytoplasm2-amino-3-carboxymuconate-6-semialdehyde decarboxylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (106)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID340739Inhibition of Chryseobacterium indologenes metallo-beta-lactamase IND-5 expressed in Escherichia coli BL21(DE3) using nitrocefin reporter substrate2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.
AID321443Inhibition of methicillin-resistant Staphylococcus aureus DHDPS at 20 mM2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Inhibiting dihydrodipicolinate synthase across species: towards specificity for pathogens?
AID1182272Protection against 40 uM zinc-acetate-induced inhibition of LYP (unknown origin) at 80 uM incubated for 30 mins at 25 degC before addition of DiFMUP substrate2014Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16
Inhibition of the lymphoid tyrosine phosphatase: the effect of zinc(II) ions and chelating ligand fragments on enzymatic activity.
AID566701Inhibition of recombinant anthrax lethal factor at 1 mM after 30 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID344916Inhibition of 2-oxoglutarate-dependent human JMJD2E in presence of excess 2-oxoglutarate and 10 uM Fe2 by FDH coupled assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases.
AID1514956Inhibition of Aeromonas hydrophila ATCC 7966 NDM1 expressed in Escherichia coli LMG194 using CPC-1 as substrate preincubated for 10 mins followed by substrate addition by fluorescence assay2019Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2
A carbapenem-based fluorescence assay for the screening of metallo-β-lactamase inhibitors.
AID1812362Inhibition of Klebsiella pneumoniae beta-lactamase IMP-28 using nitrocefin chromogenic substrate measured after 15 to 60 min at 25 degC by microplate reader2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Novel Cephalosporin Conjugates Display Potent and Selective Inhibition of Imipenemase-Type Metallo-β-Lactamases.
AID1451134Binding affinity to bacterial NDM-1 expressed in Escherichia coli BL21(DE3) assessed as intrinsic tryptophan fluorescence quenching up to 32 uM after 30 mins by luminescence spectrometric method relative to control2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-β-lactamase-1.
AID1182270Inhibition of LYP (unknown origin) at 20 to 100 uM incubated for 30 mins at 25 degC before addition of DiFMUP substrate2014Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16
Inhibition of the lymphoid tyrosine phosphatase: the effect of zinc(II) ions and chelating ligand fragments on enzymatic activity.
AID1812351Inhibition of Metallo-beta-lactamase VIM-2 in Escherichia coli clinical isolate assessed as MIC for meropenem antibacterial activity at 32 ug/ml (Rvb = 4 ug/ml)2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Novel Cephalosporin Conjugates Display Potent and Selective Inhibition of Imipenemase-Type Metallo-β-Lactamases.
AID1128912Inhibition of metallo-beta-lactamase BcII (unknown origin)2014European journal of medicinal chemistry, Apr-09, Volume: 76The applications of binuclear metallohydrolases in medicine: recent advances in the design and development of novel drug leads for purple acid phosphatases, metallo-β-lactamases and arginases.
AID566706Inhibition of human recombinant MMP9 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1451128Binding affinity to bacterial CoCoNDM-1 expressed in Escherichia coli BL21(DE3) assessed as metal stripping at 1 to 2 equiv after 30 mins by UV-Visible spectroscopic method2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-β-lactamase-1.
AID566699Inhibition of mushroom tyrosinase at 1 mM after 10 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID56936Inhibitory activity against dihydrodipicolinic acid synthase was determined1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
New analgesic drugs derived from phencyclidine.
AID1451101Inhibition of Pseudomonas aeruginosa VIM2 expressed in Escherichia coli BL21(DE3) at 50 uM using chromacef as substrate preincubated for 10 mins followed by substrate addition measured after 20 mins by HTS assay relative to control2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-β-lactamase-1.
AID344919Inhibition of 2-oxoglutarate-dependent human JMJD2E in presence of 50 uM Fe by FDH coupled assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases.
AID1812350Inhibition of Metallo-beta-lactamase IMP-28 in Klebsiella pneumoniae clinical isolate assessed as MIC for meropenem antibacterial activity at 128 ug/ml (Rvb = 2 ug/ml)2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Novel Cephalosporin Conjugates Display Potent and Selective Inhibition of Imipenemase-Type Metallo-β-Lactamases.
AID1453183Binding affinity to CK2alpha (unknown origin) assessed as change in melting temperature by thermal shift assay2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
A fragment-based approach leading to the discovery of a novel binding site and the selective CK2 inhibitor CAM4066.
AID1812361Inhibition of Enterobacter cloacae IMP-1 using nitrocefin chromogenic substrate measured after 15 to 60 min at 25 degC by microplate reader2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Novel Cephalosporin Conjugates Display Potent and Selective Inhibition of Imipenemase-Type Metallo-β-Lactamases.
AID1812382Inhibition of Metallo-beta-lactamase IMP-28 in Klebsiella pneumoniae clinical isolate assessed as fold reduction in meropenem MIC at 64 ug/ml2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Novel Cephalosporin Conjugates Display Potent and Selective Inhibition of Imipenemase-Type Metallo-β-Lactamases.
AID1812342Inhibition of Metallo-beta-lactamase NDM-1 in Escherichia coli clinical isolate assessed as MIC for meropenem antibacterial activity at 32 ug/ml (Rvb = 32 ug/ml)2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Novel Cephalosporin Conjugates Display Potent and Selective Inhibition of Imipenemase-Type Metallo-β-Lactamases.
AID321444Inhibition of Escherichia coli NAL at 20 mM2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Inhibiting dihydrodipicolinate synthase across species: towards specificity for pathogens?
AID323614Inhibition of Pseudomonas aeruginosa 101/1477 metallo beta lactamase IMP1 expressed in in Escherichia coli assessed as residual enzyme activity at 100 uM in presence of zinc chloride2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID1812380Inhibition of Metallo-beta-lactamase IMP-1 in Enterobacter cloacae clinical isolate assessed as fold reduction in meropenem MIC at 128 ug/ml2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Novel Cephalosporin Conjugates Display Potent and Selective Inhibition of Imipenemase-Type Metallo-β-Lactamases.
AID1514955Inhibition of Aeromonas hydrophila ATCC 7966 CphA expressed in Escherichia coli LMG194 using CPC-1 as substrate preincubated for 10 mins followed by substrate addition by fluorescence assay2019Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2
A carbapenem-based fluorescence assay for the screening of metallo-β-lactamase inhibitors.
AID1812384Inhibition of Metallo-beta-lactamase VIM-2 in Escherichia coli clinical isolate assessed as fold reduction in meropenem MIC at 32 ug/ml2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Novel Cephalosporin Conjugates Display Potent and Selective Inhibition of Imipenemase-Type Metallo-β-Lactamases.
AID1451100Inhibition of Serratia marcescens IMP1 expressed in Escherichia coli BL21(DE3) at 50 uM using chromacef as substrate preincubated for 10 mins followed by substrate addition measured after 20 mins by HTS assay relative to control2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-β-lactamase-1.
AID1451130Binding affinity to bacterial NDM-1 expressed in Escherichia coli BL21(DE3) assessed as Zn2+ stripping up to 128 uM after 30 mins by equilibrium dialysis method2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-β-lactamase-1.
AID1744124Competitive inhibition of human ACMSD using ACMS substrate by spectrometry2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Diflunisal Derivatives as Modulators of ACMS Decarboxylase Targeting the Tryptophan-Kynurenine Pathway.
AID1451106Inhibition of Serratia marcescens IMP1 expressed in Escherichia coli BL21(DE3) using chromacef as substrate preincubated for 10 mins followed by substrate addition measured after 20 mins by HTS assay2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-β-lactamase-1.
AID1812364Inhibition of Escherichia coli beta-lactamase VIM-2 using nitrocefin chromogenic substrate measured after 15 to 60 min at 25 degC by microplate reader2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Novel Cephalosporin Conjugates Display Potent and Selective Inhibition of Imipenemase-Type Metallo-β-Lactamases.
AID1812383Inhibition of Metallo-beta-lactamase IMP-28 in Klebsiella pneumoniae clinical isolate assessed as fold reduction in meropenem MIC at 128 ug/ml2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Novel Cephalosporin Conjugates Display Potent and Selective Inhibition of Imipenemase-Type Metallo-β-Lactamases.
AID321441Inhibition of Bacillus anthracis DHDPS at 20 mM2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Inhibiting dihydrodipicolinate synthase across species: towards specificity for pathogens?
AID1514962Inhibition of Aeromonas hydrophila ATCC 7966 NDM1 expressed in Escherichia coli LMG194 using imipenem as substrate2019Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2
A carbapenem-based fluorescence assay for the screening of metallo-β-lactamase inhibitors.
AID1812347Inhibition of Metallo-beta-lactamase IMP-1 in Enterobacter cloacae clinical isolate assessed as MIC for meropenem antibacterial activity at 128 ug/ml (Rvb = 32 ug/ml)2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Novel Cephalosporin Conjugates Display Potent and Selective Inhibition of Imipenemase-Type Metallo-β-Lactamases.
AID1363739Inhibition of Influenza A (A/California/04/2009) (H1N1) clinical isolate N-terminal truncated PA endonuclease using 5'-FAM/3-TAMRA quencer labeled 17-mer ssDNA-oligo as substrate measured over 45 mins by FRET assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Structure-Activity Relationships in Metal-Binding Pharmacophores for Influenza Endonuclease.
AID323617Inhibition of metallo beta lactamase VIM4 assessed as residual enzyme activity at 100 uM2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID323618Inhibition of Aeromonas hydrophila metallo beta lactamase CphA assessed as residual enzyme activity at 100 uM in absence of zinc2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID1451123Binding affinity to bacterial CoCoNDM-1 expressed in Escherichia coli BL21(DE3) assessed as metal stripping at 1 to 2 equiv by 1H NMR spectroscopic method2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-β-lactamase-1.
AID200368Beta-Lactamase inhibitory activity against represent active class A (TEM-1) serine enzyme; NT= Not tested2004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
Penicillin-derived inhibitors that simultaneously target both metallo- and serine-beta-lactamases.
AID1812349Inhibition of Metallo-beta-lactamase IMP-28 in Klebsiella pneumoniae clinical isolate assessed as MIC for meropenem antibacterial activity at 64 ug/ml (Rvb = 2 ug/ml)2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Novel Cephalosporin Conjugates Display Potent and Selective Inhibition of Imipenemase-Type Metallo-β-Lactamases.
AID107428Beta-Lactamase Inhibition of metallo-beta-lactamase representative class B (L1) enzyme2004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
Penicillin-derived inhibitors that simultaneously target both metallo- and serine-beta-lactamases.
AID1812379Inhibition of Metallo-beta-lactamase IMP-1 in Enterobacter cloacae clinical isolate assessed as fold reduction in meropenem MIC at 64 ug/ml2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Novel Cephalosporin Conjugates Display Potent and Selective Inhibition of Imipenemase-Type Metallo-β-Lactamases.
AID1812348Inhibition of Metallo-beta-lactamase IMP-28 in Klebsiella pneumoniae clinical isolate assessed as MIC for meropenem antibacterial activity at 32 ug/ml (Rvb = 2 ug/ml)2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Novel Cephalosporin Conjugates Display Potent and Selective Inhibition of Imipenemase-Type Metallo-β-Lactamases.
AID344917Inhibition of 2-oxoglutarate-dependent human JMJD2E in presence of excess H3K9me3 peptide and 10 uM Fe2 by FDH coupled assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases.
AID566703Inhibition of human recombinant MMP2 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID323613Inhibition of Pseudomonas aeruginosa 101/1477 metallo beta lactamase IMP1 expressed in in Escherichia coli assessed as residual enzyme activity at 100 uM in absence of zinc2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID107427Inhibition of class B (BCII) metallo-beta-lactamase representative enzyme2004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
Penicillin-derived inhibitors that simultaneously target both metallo- and serine-beta-lactamases.
AID1812389Inhibition of Metallo-beta-lactamase NDM-1 in Escherichia coli clinical isolate assessed as fold reduction in meropenem MIC at 128 ug/ml2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Novel Cephalosporin Conjugates Display Potent and Selective Inhibition of Imipenemase-Type Metallo-β-Lactamases.
AID1679133Zinc chelating activity mediated inhibition of Clostridium botulinum BoNT/A1 LC (1 to 425 residues) activity using SNAPtide as substrate at 1 mM incubated with enzyme for 30 mins followed by substrate addition and measured for 20 mins by FRET assay relati
AID1514961Inhibition of Aeromonas hydrophila ATCC 7966 CphA expressed in Escherichia coli LMG194 using imipenem as substrate2019Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2
A carbapenem-based fluorescence assay for the screening of metallo-β-lactamase inhibitors.
AID1812387Inhibition of Metallo-beta-lactamase NDM-1 in Escherichia coli clinical isolate assessed as fold reduction in meropenem MIC at 32 ug/ml2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Novel Cephalosporin Conjugates Display Potent and Selective Inhibition of Imipenemase-Type Metallo-β-Lactamases.
AID1812388Inhibition of Metallo-beta-lactamase NDM-1 in Escherichia coli clinical isolate assessed as fold reduction in meropenem MIC at 64 ug/ml2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Novel Cephalosporin Conjugates Display Potent and Selective Inhibition of Imipenemase-Type Metallo-β-Lactamases.
AID566707Inhibition of mouse recombinant iNOS at 1 mM after 40 mins by colorimetric assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1451125Metal chelating activity assessed as Co2+-compound complex formation at 1 equiv by 1H NMR spectroscopic method2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-β-lactamase-1.
AID344918Inhibition of 2-oxoglutarate-dependent human JMJD2E preincubated for 30 mins by FDH coupled assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases.
AID1812378Inhibition of Metallo-beta-lactamase IMP-1 in Enterobacter cloacae clinical isolate assessed as fold reduction in meropenem MIC at 32 ug/ml2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Novel Cephalosporin Conjugates Display Potent and Selective Inhibition of Imipenemase-Type Metallo-β-Lactamases.
AID1071812Noncompetitive inhibition of Bacillus subtilis glutamate racemase2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
Inhibition of glutamate racemase by substrate-product analogues.
AID1812352Inhibition of Metallo-beta-lactamase VIM-2 in Escherichia coli clinical isolate assessed as MIC for meropenem antibacterial activity at 64 ug/ml (Rvb = 4 ug/ml)2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Novel Cephalosporin Conjugates Display Potent and Selective Inhibition of Imipenemase-Type Metallo-β-Lactamases.
AID1514958Inhibition of Aeromonas hydrophila ATCC 7966 CphA expressed in Escherichia coli LMG194 using FC3 as substrate preincubated for 10 mins followed by substrate addition by fluorescence assay2019Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2
A carbapenem-based fluorescence assay for the screening of metallo-β-lactamase inhibitors.
AID323615Inhibition of Bacillus cereus metallo beta lactamase Bc2 assessed as residual enzyme activity at 100 uM2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID530343Inhibition of Pseudomonas aeruginosa VIM-1 beta-lactamase after 10 mins2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID1451127Binding affinity to bacterial CoCoNDM-1 expressed in Escherichia coli BL21(DE3) assessed as CoCoNDM-1-compound ternary complex formation at 1 equiv by 1H EPR spectroscopic method2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-β-lactamase-1.
AID321440Inhibition of Escherichia coli DHDPS at 20 mM2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Inhibiting dihydrodipicolinate synthase across species: towards specificity for pathogens?
AID1812345Inhibition of Metallo-beta-lactamase IMP-1 in Enterobacter cloacae clinical isolate assessed as MIC for meropenem antibacterial activity at 32 ug/ml (Rvb = 32 ug/ml)2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Novel Cephalosporin Conjugates Display Potent and Selective Inhibition of Imipenemase-Type Metallo-β-Lactamases.
AID1812381Inhibition of Metallo-beta-lactamase IMP-28 in Klebsiella pneumoniae clinical isolate assessed as fold reduction in meropenem MIC at 32 ug/ml2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Novel Cephalosporin Conjugates Display Potent and Selective Inhibition of Imipenemase-Type Metallo-β-Lactamases.
AID1128911Inhibition of metallo-beta-lactamase L1 (unknown origin)2014European journal of medicinal chemistry, Apr-09, Volume: 76The applications of binuclear metallohydrolases in medicine: recent advances in the design and development of novel drug leads for purple acid phosphatases, metallo-β-lactamases and arginases.
AID566705Inhibition of human recombinant MMP8 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID321442Inhibition of Mycobacterium tuberculosis DHDPS at 20 mM2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Inhibiting dihydrodipicolinate synthase across species: towards specificity for pathogens?
AID530344Inhibition of Pseudomonas aeruginosa VIM-13 beta-lactamase after 10 mins2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID566700Inhibition of human recombinant 5-lipoxygenase at 1 mM after 10 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID313850Inhibition of dihydrodipicolinate synthase2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Conformationally constrained diketopimelic acid analogues as inhibitors of dihydrodipicolinate synthase.
AID323619Inhibition of Stenotrophomonas maltophilia metallo beta lactamase L1 assessed as residual enzyme activity at 100 uM2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID323620Inhibition of Legionella gormani beta lactamase metallo FEZ1 expressed in Escherichia coli assessed as residual enzyme activity at 100 uM2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID1812343Inhibition of Metallo-beta-lactamase NDM-1 in Escherichia coli clinical isolate assessed as MIC for meropenem antibacterial activity at 64 ug/ml (Rvb = 32 ug/ml)2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Novel Cephalosporin Conjugates Display Potent and Selective Inhibition of Imipenemase-Type Metallo-β-Lactamases.
AID1071813Inhibition of Bacillus subtilis glutamate racemase2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
Inhibition of glutamate racemase by substrate-product analogues.
AID323616Inhibition of metallo beta lactamase VIM2 assessed as residual enzyme activity at 100 uM2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID1812346Inhibition of Metallo-beta-lactamase IMP-1 in Enterobacter cloacae clinical isolate assessed as MIC for meropenem antibacterial activity at 64 ug/ml (Rvb = 32 ug/ml)2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Novel Cephalosporin Conjugates Display Potent and Selective Inhibition of Imipenemase-Type Metallo-β-Lactamases.
AID1812386Inhibition of Metallo-beta-lactamase VIM-2 in Escherichia coli clinical isolate assessed as fold reduction in meropenem MIC at 128 ug/ml2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Novel Cephalosporin Conjugates Display Potent and Selective Inhibition of Imipenemase-Type Metallo-β-Lactamases.
AID1812385Inhibition of Metallo-beta-lactamase VIM-2 in Escherichia coli clinical isolate assessed as fold reduction in meropenem MIC at 64 ug/ml2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Novel Cephalosporin Conjugates Display Potent and Selective Inhibition of Imipenemase-Type Metallo-β-Lactamases.
AID1514957Inhibition of Aeromonas hydrophila ATCC 7966 IMP1 expressed in Escherichia coli LMG194 using CPC-1 as substrate preincubated for 10 mins followed by substrate addition by fluorescence assay2019Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2
A carbapenem-based fluorescence assay for the screening of metallo-β-lactamase inhibitors.
AID200370Beta-Lactamase inhibitory activity against represent active class C (P99) serine enzyme; NT= Not tested2004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
Penicillin-derived inhibitors that simultaneously target both metallo- and serine-beta-lactamases.
AID1812363Inhibition of Escherichia coli beta-lactamase NDM-1 using nitrocefin chromogenic substrate measured after 15 to 60 min at 25 degC by microplate reader2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Novel Cephalosporin Conjugates Display Potent and Selective Inhibition of Imipenemase-Type Metallo-β-Lactamases.
AID1514963Inhibition of Aeromonas hydrophila ATCC 7966 IMP1 expressed in Escherichia coli LMG194 using imipenem as substrate2019Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2
A carbapenem-based fluorescence assay for the screening of metallo-β-lactamase inhibitors.
AID1812353Inhibition of Metallo-beta-lactamase VIM-2 in Escherichia coli clinical isolate assessed as MIC for meropenem antibacterial activity at 128 ug/ml (Rvb = 4 ug/ml)2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Novel Cephalosporin Conjugates Display Potent and Selective Inhibition of Imipenemase-Type Metallo-β-Lactamases.
AID566702Inhibition of human recombinant MMP1 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1451104Inhibition of bacterial MBP-fused NDM1 expressed in Escherichia coli BL21(DE3) ausing fluorocillin as substrate preincubated for 20 mins followed by substrate addition measured at 1 sec time interval for 25 mins by fluorescence assay2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-β-lactamase-1.
AID1451102Inhibition of bacterial MBP-fused NDM1 expressed in Escherichia coli BL21(DE3) at 50 uM using chromacef as substrate preincubated for 10 mins followed by substrate addition measured after 20 mins by HTS assay relative to control2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-β-lactamase-1.
AID1514959Inhibition of Aeromonas hydrophila ATCC 7966 NDM1 expressed in Escherichia coli LMG194 using FC3 as substrate preincubated for 10 mins followed by substrate addition by fluorescence assay2019Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2
A carbapenem-based fluorescence assay for the screening of metallo-β-lactamase inhibitors.
AID1451105Inhibition of bacterial MBP-fused NDM1 expressed in Escherichia coli BL21(DE3) ausing fluorocillin as substrate preincubated for 20 mins followed by substrate addition measured at 1 sec time interval for 25 mins in presence of ZnSO4 by fluorescence assay2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-β-lactamase-1.
AID1744123Inhibition of ACMSD (unknown origin)2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Diflunisal Derivatives as Modulators of ACMS Decarboxylase Targeting the Tryptophan-Kynurenine Pathway.
AID1812344Inhibition of Metallo-beta-lactamase NDM-1 in Escherichia coli clinical isolate assessed as MIC for meropenem antibacterial activity at 128 ug/ml (Rvb = 32 ug/ml)2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Novel Cephalosporin Conjugates Display Potent and Selective Inhibition of Imipenemase-Type Metallo-β-Lactamases.
AID1451107Inhibition of Pseudomonas aeruginosa VIM2 expressed in Escherichia coli BL21(DE3) using chromacef as substrate preincubated for 10 mins followed by substrate addition measured after 20 mins by HTS assay2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-β-lactamase-1.
AID566704Inhibition of human recombinant MMP3 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1514960Inhibition of Aeromonas hydrophila ATCC 7966 IMP1 expressed in Escherichia coli LMG194 using FC3 as substrate preincubated for 10 mins followed by substrate addition by fluorescence assay2019Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2
A carbapenem-based fluorescence assay for the screening of metallo-β-lactamase inhibitors.
AID1451103Inhibition of bacterial MBP-fused NDM1 expressed in Escherichia coli BL21(DE3) ausing chromacef as substrate preincubated for 20 mins followed by substrate addition measured after 0.3 mins2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-β-lactamase-1.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2015Proteins, Jan, Volume: 83, Issue:1
Human α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD): a structural and mechanistic unveiling.
AID1798635FDH Coupled Inhibition Assay from Article 10.1021/jm800936s: \\Inhibitor Scaffolds for 2-Oxoglutarate-Dependent Histone Lysine Demethylases.\\2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (584)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990103 (17.64)18.7374
1990's48 (8.22)18.2507
2000's161 (27.57)29.6817
2010's218 (37.33)24.3611
2020's54 (9.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 53.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index53.80 (24.57)
Research Supply Index6.39 (2.92)
Research Growth Index4.82 (4.65)
Search Engine Demand Index88.11 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (53.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews7 (1.18%)6.00%
Case Studies1 (0.17%)4.05%
Observational0 (0.00%)0.25%
Other584 (98.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]